ALK and peripheral T-cell lymphoma, not otherwise specified: The enrolled patients including 4 (30.8%) with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), 3 (23.1%) with angioimmunoblastic T-cell lymphoma (AITL), 2 (15.4%) with anaplastic lymphoma kinase (ALK)-negative angiotropic large cell lymphoma (ALK- ALCL), 1 (7.7%) with ALK-positive ALCL (ALK+ ALCL), 1 (7.7%) with cutaneous T-cell lymphoma (CTCL), 1 (7.7%) with nodal TFH lymphoma, follicular-type (nTFHL-F), and 1 (7.7%) with monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL).